Jo Cambridge, a pioneering scientist whose research on rheumatoid arthritis led to life-changing immunotherapies, has died aged 73. Her work, conducted over four decades, challenged prevailing medical dogma and transformed the treatment landscape for autoimmune diseases globally.
Early Life and Education in Australia
Born in Perth, Australia, to Judith and Geoffrey Cambridge, Jo excelled academically from a young age. After attending Presbyterian Ladies College, she pursued a BSc at the University of Western Australia, graduating in 1974. Science was her passion, but she also enjoyed a vibrant social life, winning Miss Rugby 1973 and working as a sought-after barmaid in local pubs.
Move to London and Career Beginnings
Soon after graduating, Jo moved to London, securing research positions at Hammersmith Hospital and then University College London (UCL). In 1984, she earned her PhD and continued her research at UCL for the rest of her career. It was here that she began her 40-year partnership with Jonathan Edwards, a collaboration that would redefine autoimmune disease treatment.
The Groundbreaking B-Cell Depletion Hypothesis
Jo and Jonathan's hypothesis was radical: using therapeutic monoclonal antibodies to deplete B-cells could fundamentally alter autoimmune diseases like rheumatoid arthritis. This idea was initially met with skepticism, but their persistence and rigorous research proved its validity.
| Key Aspect | Jo Cambridge's Contribution |
|---|---|
| Research Focus | Rheumatoid arthritis and B-cell biology |
| Main Hypothesis | B-cell depletion via monoclonal antibodies |
| Impact | Led to development of rituximab and other immunotherapies |
| Legacy | Improved lives of millions with autoimmune diseases |
How B-Cell Depletion Works
B-cells are a type of white blood cell that produces antibodies. In autoimmune diseases, they mistakenly attack healthy tissues. By depleting these cells, the immune system can reset and reduce inflammation, offering relief to patients who had exhausted other options.
Impact on Immunotherapy and Patient Lives
The research by Jo and Jonathan paved the way for the use of rituximab, originally a cancer drug, as a treatment for rheumatoid arthritis. Today, it is a standard therapy, and their work has influenced the development of other B-cell-targeting drugs for conditions like lupus and multiple sclerosis.
- Rituximab is now a first-line treatment for severe rheumatoid arthritis.
- Their hypothesis expanded understanding of autoimmune disease mechanisms.
- Jo's work inspired a new generation of researchers in immunotherapy.
Remembering Jo Cambridge
Jo was known for her sharp intellect, her willingness to challenge established ideas, and her warm, engaging personality. She was a mentor to many and a beloved colleague. Her death from acute myeloid leukaemia is a great loss to the scientific community, but her legacy lives on in the countless patients who have benefited from her research.
FAQ
What did Jo Cambridge discover?
How did Jo Cambridge's research impact rheumatoid arthritis treatment?
What is B-cell depletion?
Best Products We’ve Tested and Rated

Our testing team has hands-on reviews of game processing kit, gifts rock climbers, shoes plantar fasciitis men, running headlamp, and camera bag. Every option below was compared across price, build quality, and real-world performance, with honest pros and cons. We update these guides regularly as new models arrive, so the recommendations stay current.
Our testing team has hands-on reviews of budget night vision, first aid kit backcountry skiing, climbing knee pads, budget mens boots, and bike rack sprinter van. Every option below was compared across price, build quality, and real-world performance, with honest pros and cons. We update these guides regularly as new models arrive, so the recommendations stay current.